POLE and cancer: MMR deficient or PolE-mutant tumors rapidly accumulate large amounts of mutations (~600 mutations/cell division), reaching but not exceeding, ~20,000 exon mutations in under six months, suggesting a threshold compatible with cancer cell survival [64].